A Multi-Centre, Randomised, Double Blind, Placebo Controlled, Parallel Group Study of TA 8995 in Patients with Mild Dyslipidaemia, Alone and In Combination with Statin Therapy

Trial Profile

A Multi-Centre, Randomised, Double Blind, Placebo Controlled, Parallel Group Study of TA 8995 in Patients with Mild Dyslipidaemia, Alone and In Combination with Statin Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2015

At a glance

  • Drugs Obicetrapib (Primary) ; Atorvastatin; Rosuvastatin
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Acronyms TULIP
  • Sponsors Xention
  • Most Recent Events

    • 01 Aug 2015 Results published in the Lancet.
    • 29 Aug 2014 Primary endpoint has been met. (Change in both HDL-C and LDL-C levels at Week 12)
    • 29 Aug 2014 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top